To observe the clinical efficacy of sodium ferulate combined with mecobalamin in the treatment of type 2 diabetic peripheral neuropathy (DPN). Methods: Seventy-eight patients diagnosed with DPN were randomly assigned to the control group and observation group with 39 cases in each. The control group was given intramuscular injections of 0.5 mg mecobalamin once per day. The observation group was given 300 mg intravenous sodium ferulate plus 0.5 mg intramuscular mecobalamin once per day. Treatment lasted 14 days for both groups. The pre- and post-treatment motor nerve conduction velocity (MCV), sensory nerve conduction velocity (SCV), and treatment efficacy in the two groups were compared. Results: Within each group, the post-treatment MCV and SCV of the median nerve and common peroneal nerve increased compared to before treatment (P<0.05), and the MCV and SCV of the median and common peroneal nerves of the observation group were greater than that of the control group (P<0.05). The total effective rate in the control group was 56.41% , and that in the observation group was significantly higher at 87.15% (P<0.05). Conclusion: Combining sodium ferulate with mecobalamin effectively enhances the clinical efficacy of mecobalamin in the treatment of DPN.